Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Researchers at University of Tsukuba identified a previously unconfirmed gas exchange threshold in rats and demonstrated that ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...

Columnist Caroline Gainer explains how cold weather aggravates her COPD and shares the methods she uses to protect her lungs ...